NEW YORK (GenomeWeb News) - Epigenomics said today that it has placed 2,671,088 new shares at an issue price of €1.94 per share, raising gross proceeds of €5.18 million ($6.6 million).

A subsidiary of BB Medtech and funds managed by Abingworth subscribed for all the new shares. The transaction will double the BB Medtech group's stake in Epigenomics to about 14.9 percent from about 7.4 percent, making it the second largest shareholder in the firm after Federated Investors. Funds managed by Abingworth will own about 11.1 percent of the company's shares.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York Times and ProPublica say that many physicians fail to disclose their financial ties when publishing in medical journals.

The Wall Street Journal reports Human Longevity's valuation has dropped by 80 percent.

Science reports that the US National Cancer Institute is cutting its operating budget by 5 percent.

In PLOS this week: similar variants seen in bullbogs, people with Robinow syndrome; ApoE genotypes in African-American, Puerto Rican populations; and more.

Dec
11
Sponsored by
PerkinElmer

This webinar describes a study that used two independent next-generation sequencing (NGS) platforms to gain insight into the impact of different types of aneuploidies during preimplantation genetic testing.

Dec
12
Sponsored by
Illumina

This webinar will discuss the use of shotgun metagenomics to identify children at risk of hospital-acquired infection.